Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Time-trend and recurrence analysis of pancreatic neuroendocrine tumors.

Kim H, Song KB, Hwang DW, Lee JH, Shadi A, Kim SC.

Endocr Connect. 2019 Jun 1. pii: EC-19-0282. doi: 10.1530/EC-19-0282. [Epub ahead of print]

2.

Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group.

Zhang XF, Wu Z, Cloyd J, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Schmidt CR, Dillhoff M, Maithel SK, Pawlik TM.

Surgery. 2019 Mar;165(3):548-556. doi: 10.1016/j.surg.2018.08.015. Epub 2018 Sep 29.

PMID:
30278986
3.

Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.

Tsutsumi K, Ohtsuka T, Fujino M, Nakashima H, Aishima S, Ueda J, Takahata S, Nakamura M, Oda Y, Tanaka M.

J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):418-25. doi: 10.1002/jhbp.47. Epub 2013 Oct 20.

PMID:
24142395
4.

Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center.

Zhou B, Duan J, Yan S, Zhou J, Zheng S.

Oncol Lett. 2017 Mar;13(3):1157-1164. doi: 10.3892/ol.2017.5561. Epub 2017 Jan 2.

5.

Significance of Lymph Node Metastasis in Resectable Well-differentiated Pancreatic Neuroendocrine Tumor.

Harimoto N, Hoshino K, Muranushi R, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Araki K, Hosouchi Y, Suzuki H, Arakawa K, Hirai K, Fukazawa T, Ikota H, Shirabe K.

Pancreas. 2019 Aug;48(7):943-947. doi: 10.1097/MPA.0000000000001355.

PMID:
31268980
6.

Resection of pancreatic neuroendocrine tumors: results of 70 cases.

Kazanjian KK, Reber HA, Hines OJ.

Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70.

PMID:
16924083
7.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
8.

Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.

Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ.

Am J Surg. 2014 Nov;208(5):775-780. doi: 10.1016/j.amjsurg.2014.04.003. Epub 2014 Jun 8.

PMID:
24997491
9.

Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors.

Zhou B, Fang B, Yan S, Wang W.

Clin Lab. 2017 Jul 1;63(7):1251-1259. doi: 10.7754/Clin.Lab.2017.170207.

PMID:
28792692
10.

The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.

Lopez-Aguiar AG, Ethun CG, Zaidi MY, Rocha FG, Poultsides GA, Dillhoff M, Fields RC, Idrees K, Cho CS, Abbott DE, Cardona K, Maithel SK.

Surgery. 2019 Jul;166(1):15-21. doi: 10.1016/j.surg.2019.03.008. Epub 2019 May 6.

PMID:
31072670
11.

Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors.

Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY.

Chin Med J (Engl). 2015 Dec 20;128(24):3335-44. doi: 10.4103/0366-6999.171427.

12.

Outcome of surgery for pancreatic neuroendocrine neoplasms.

Fischer L, Bergmann F, Schimmack S, Hinz U, Prieß S, Müller-Stich BP, Werner J, Hackert T, Büchler MW.

Br J Surg. 2014 Oct;101(11):1405-12. doi: 10.1002/bjs.9603. Epub 2014 Aug 13.

PMID:
25132004
13.

Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.

Xiang JX, Zhang XF, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM.

J Surg Oncol. 2018 Dec;118(7):1096-1104. doi: 10.1002/jso.25246. Epub 2018 Sep 27.

PMID:
30261105
14.

Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.

Kim DW, Kim HJ, Kim KW, Byun JH, Kim SY, Song KB, Ramaiya NH, Tirumani SH, Hong SM.

Eur Radiol. 2016 May;26(5):1320-9. doi: 10.1007/s00330-015-3943-5. Epub 2015 Aug 8.

PMID:
26253259
15.

Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.

Yang M, Ke NW, Zeng L, Zhang Y, Tan CL, Zhang H, Mai G, Tian BL, Liu XB.

Medicine (Baltimore). 2015 Dec;94(48):e2156. doi: 10.1097/MD.0000000000002156. Erratum in: Medicine (Baltimore). 2016 Feb;95(6):e507d. Medicine (Baltimore). 2016 Feb 12;95(6):e507d.

16.

Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.

Harimoto N, Hoshino K, Muranushi R, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Tanaka H, Watanabe A, Kubo N, Araki K, Hosouchi Y, Suzuki H, Arakawa K, Hirai K, Fukazawa T, Ikota H, Shirabe K.

Pancreatology. 2019 Sep;19(6):897-902. doi: 10.1016/j.pan.2019.08.003. Epub 2019 Aug 7.

PMID:
31409525
17.

Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China.

Jin K, Luo G, Xu J, Zhang B, Liu C, Ji S, Liu L, Long J, Ni Q, Yu X.

Oncol Lett. 2017 May;13(5):3163-3168. doi: 10.3892/ol.2017.5834. Epub 2017 Mar 9.

18.

Lymph node ratio, but not the total number of examined lymph nodes or lymph node metastasis, is a predictor of overall survival for pancreatic neuroendocrine neoplasms after surgical resection.

Liu P, Zhang X, Shang Y, Lu L, Cao F, Sun M, Tang Z, Vollmar B, Gong P.

Oncotarget. 2017 Jul 12;8(51):89245-89255. doi: 10.18632/oncotarget.19184. eCollection 2017 Oct 24.

19.

A single institution's 21-year experience with surgically resected pancreatic neuroendocrine tumors: an analysis of survival and prognostic factors.

Cienfuegos JA, Rotellar F, Salguero J, Ruiz-Canela M, Núñez Córdoba JM, Sola I, Benito A, Martí-Cruchaga P, Zozaya G, Pardo F, Hernández Lizoáin JL.

Rev Esp Enferm Dig. 2016 Nov;108(11):689-696.

20.

Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors.

Arima K, Okabe H, Hashimoto D, Chikamoto A, Nitta H, Higashi T, Kaida T, Yamamura K, Kitano Y, Komohara Y, Yamashita YI, Beppu T, Takeya M, Baba H.

Int J Clin Oncol. 2017 Aug;22(4):734-739. doi: 10.1007/s10147-017-1111-4. Epub 2017 Mar 11.

PMID:
28285371

Supplemental Content

Support Center